The team behind the vision

Dr. Michael Centola is an immunologist and inflammatory disease expert with over 30 years of experience in turning cutting-edge science into real-world health solutions. He earned his Ph.D. in Molecular Biology & Biochemistry and became a pioneer in translating laboratory breakthroughs into patient care. Dr. Centola helped develop the first genetic and the first molecular diagnostic test for a rheumatologic disease. He has authored over 100 scientific publications while securing numerous patents in inflammatory disease therapy and device development. An advocate for evidence-based natural medicine, he has been instrumental in applying rigorous scientific standards to herbal therapy development. Today, Dr. Centola's expertise drives Nanocur's mission to enhance the power of natural remedies. He is a coinventor of Nanocur's advanced curcumin formulation—a breakthrough that overcomes curcumin's notoriously poor bioavailability. By using a patented plant-based nanoparticle carrier (covered by US Patent 10,968,260 and WO2023023648A1), this formulation protects curcumin from stomach acid and optimizes its absorption. The result is a curcumin therapy that delivers over 100 times the bioactive potency of ordinary turmeric, offering faster, more effective benefits at an affordable cost. Under Dr. Centola's leadership, Nanocur is turning cutting-edge science into accessible wellness—making advanced natural therapies safer, more effective, and affordable.

Dr. Philip Alex, M.D., Ph.D. obtained his Ph.D. in neuro-immunology and has over 20 years of experience in autoimmune, inflammatory, and translational research. His rigorous research and development leadership helped shape Haus’s evidence-based approach, bridging the gap between natural remedies and traditional medicine. Dr. Alex has been instrumental in the development of NanoCur, guiding its advanced formulation science, targeted anti-inflammatory design, and clinical strategy. He co-invented all of Haus’s curcumin delivery innovations – including patents US10968260B2 and WO2023023648A1 – which use natural nanotechnology breakthroughs to dramatically enhance curcumin absorption and potency. Beyond curcumin, Dr. Alex’s pioneering studies have unlocked key insights and novel therapies for inflammatory diseases like eczema, psoriasis, rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and viral infection, which includes numerous scientific publications and patents in the space. He combines deep scientific expertise with a patient-focused vision, translating cutting-edge science into natural solutions that improve lives.

Dr. Christopher Sutton serves as Vice President of Quality for Nanocur, where he is responsible for production oversight, quality management systems, regulatory compliance, and operational optimization. Bringing extensive experience from the pharmaceutical, biotech, clinical diagnostics, and product testing sectors, Dr. Sutton has specialized in designing and managing regulated facilities since 2002 including programs in pharmaceuticals, active pharmaceutical ingredients, dietary supplements, clinical diagnostics, and product testing according to cGMP, cGLP, ISO, and CLIA standards. Dr. Sutton holds a Ph.D. in Biological Chemistry from UCLA Molecular Biology Institute. Prior to focusing on regulated production, his work in the biotech industry centered on developing treatments and clinical tests for inflammatory, autoimmune, and infectious diseases, an expertise that has played a significant role in the development of Nanocur.

Dr. Datta oversees contract research and international manufacturing operations at Haus with a focus on herbal and nutraceutical product development, guiding products from raw material sourcing to finished formulation. His expertise informed key aspects of the Nanocur development program and contributed to its technical refinement and advancement within Haus Bioceuticals. Backed by over three decades of experience, he previously spent 17 years at Panacea Biotec, where he played a pivotal role in setting up laboratories and herbal extraction plants, led the development and launch of India’s first herbal drug approved by the Drug Authority, and formulated numerous herbal OTCs, nutraceuticals, cosmeceuticals, and supplements for global markets. At Bambino Group, as Vice President R&D, he established their research infrastructure and directed the development of a broad range of functional food and dietary supplement products. Dr. Datta has conducted research on over 45 medicinal plants, developed novel extraction and purification processes for phytochemical markers, and is credited with 11 patents and 14 publications.